IP Library Granted Patent US 9,290,815
Granted Patent B2
US 9,290,815 · App. 14/000,096 · Granted Mar 22, 2016

Method for quantifying human DNA

Inventors: Francesca Di Pasquale (Hilden, DE); Holger Engel (Hilden, DE)
Assignee: Qiagen GMBH
C12Q1/6888C12Q1/6851C12Q1/6876C12Q2600/166
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,290,815
App. No.
14/000,096
Granted
Mar 22, 2016
Kind
B2
Abstract

The invention provides for a method for quantifying one or more nucleic acids of a genome in a sample comprising the steps of, (a) amplifying a first nucleic acid to be quantified, (b) determining the amount of said first nucleic acid by comparison of the amount of amplification product from said first nucleic acid with at least one amplification product from a second template nucleic acid, (c) wherein said second template nucleic acid was generated using whole genome amplification and wherein the starting concentration of the second template nucleic acid is known.

Claims (29)

1. Method for quantifying one or more nucleic acids of a genome in a sample comprising the steps of,

a. amplifying a first nucleic acid to be quantified from a first template nucleic acid,

b. determining the amount of said first nucleic acid by comparison of the amount of a first amplification product from said first nucleic acid with at least one second amplification product from a second template nucleic acid,

c. wherein said second template nucleic acid was generated using whole genome amplification and wherein the starting concentration of the second template nucleic acid is known; and

wherein the second amplification product comprises a sequence at least 60% identical to SEQ ID NO: 1 over a stretch of 80 contiguous base pairs.

2. Method according to claim 1 , wherein the nucleic acid sequences of the first nucleic acid and second template nucleic acid are from the same organism.

3. Method according to claim 1 , wherein the nucleic acids are DNA.

4. Method according to claim 1 , wherein the nucleic acid sequences of the first and second template nucleic acid are of human origin.

5. Method according to claim 1 , wherein said second template nucleic acid is from a nucleic acid mixture from various individuals of a given type of organism.

6. Method according to claim 1 , wherein said second template nucleic acid was generated using two or more rounds of whole genome amplification.

7. Method according to claim 1 , wherein the comparison is done with two or more second amplification products from said second template nucleic acids, wherein the two or more second amplification products are generated from different starting concentrations of said second template nucleic acids.

8. Method according to claim 7 , wherein the different starting concentrations of said second template nucleic acid have been adjusted in such a way that they reflect a substantially linear range of concentrations.

9. Method according to claim 1 , wherein the second template nucleic acid comprises primarily human nucleic acid sequences and its origin is selected from one of the following samples: blood, whole blood, fractions of blood, isolated nucleated blood cells, buccal swabs, saliva, sputum, urine and biopsies.

10. Method according to claim 1 , wherein the amplification reaction of the first nucleic acid to be amplified comprises an internal control nucleic acid.

11. Method according to claim 1 , wherein the amplification process is a real-time amplification process.

12. Method according to claim 11 , wherein a Ct value is obtained from the real-time amplification process and is compared with a standard curve generated using different dilutions of the second template nucleic acid.

13. The method of claim 1 , wherein the second amplification product comprises a sequence at least 70% identical to SEQ ID NO: 1 over a stretch of 80 contiguous base pairs.

14. The method of claim 1 , wherein the second amplification product comprises a sequence at least 80% identical to SEQ ID NO: 1 over a stretch of 80 contiguous base pairs.

15. The method of claim 1 , wherein the second amplification product comprises a sequence at least 90% identical to SEQ ID NO: 1 over a stretch of 80 contiguous base pairs.

16. The method of claim 1 , wherein the second amplification product comprises a sequence at least 95% identical to SEQ ID NO: 1 over a stretch of 80 contiguous base pairs.

17. The method of claim 1 , wherein the second amplification product comprises a sequence at least 98% identical to SEQ ID NO: 1 over a stretch of 80 contiguous base pairs.

18. The method of claim 1 wherein the sequence is SEQ ID NO: 1.

19. The method of claim 1 , wherein the sequence at least 60% identical to SEQ ID NO: 1 over a stretch of 80 contiguous base pairs is present in at least 10 copies in the second template nucleic acid.

20. The method of claim 1 , wherein the sequence at least 60% identical to SEQ ID NO: 1 over a stretch of 80 contiguous base pairs is present in at least 20 copies in the second template nucleic acid.

21. The method of claim 1 , wherein the sequence at least 60% identical to SEQ ID NO: 1 over a stretch of 80 contiguous base pairs is present in at least 29 copies in the second template nucleic acid.

22. The method of claim 1 , wherein the sequence at least 60% identical to SEQ ID NO: 1 over a stretch of 80 contiguous base pairs is present on a human chromosome selected from the group consisting of chromosomes 1, 4, 5, 7, 11 and 16.

23. The method of claim 1 , wherein a primer is used to amplify the sequence at least 60% identical to SEQ ID NO: 1 over a stretch of 80 contiguous base pairs and wherein the primer is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12.

24. The method of claim 1 , wherein a primer is used to amplify the sequence at least 60% identical to SEQ ID NO: 1 over a stretch of 80 contiguous base pairs and wherein the primer differs from a polynucleotide selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: 12; by no more than 5 nucleotides over a stretch of 18 contiguous nucleotides.

25. The method of claim 1 , wherein two primers are used to amplify the sequence at least 60% identical to SEQ ID NO: 1 over a stretch of 80 contiguous base pairs and wherein the primers are SEQ ID NO: 11 and SEQ ID NO: 12.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2013
From: DI PASQUALE, FRANCESCA; ENGEL, HOLGER
To: QIAGEN GMBH
Reel/Frame 031780/0411 →
Priority Claims (1)
EP 11155164 · Feb 21, 2011 · regional
Continuity (1)
Related Publication 20140234834A1 · Aug 21, 2014